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Introduction: The incidence of acute pancreatitis (AP) and the prevalence of metabolic
syndrome (MetS) are growing worldwide. Several studies have confirmed that obesity
(OB), hyperlipidemia (HL), or diabetes mellitus (DM) can increase severity, mortality,
and complications in AP. However, there is no comprehensive information on the
independent or joint effect of MetS components on the outcome of AP. Our aims were
(1) to understand whether the components of MetS have an independent effect on the
outcome of AP and (2) to examine the joint effect of their combinations.
Methods: From 2012 to 2017, 1435 AP cases from 28 centers were included in
the prospective AP Registry. Patient groups were formed retrospectively based on the
presence of OB, HL, DM, and hypertension (HT). The primary endpoints were mortality,
severity, complications of AP, and length of hospital stay. Odds ratio (OR) with 95%
confidence intervals (CIs) were calculated.
Results: 1257 patients (55.7 ± 17.0 years) were included in the analysis. The presence
of OB was an independent predictive factor for renal failure [OR: 2.98 (CI: 1.33–6.66)]
and obese patients spent a longer time in hospital compared to non-obese patients
(12.1 vs. 10.4 days, p = 0.008). HT increased the risk of severe AP [OR: 3.41 (CI:
1.39–8.37)], renal failure [OR: 7.46 (CI: 1.61–34.49)], and the length of hospitalization
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(11.8 vs. 10.5 days, p = 0.020). HL increased the risk of local complications [OR: 1.51
(CI: 1.10–2.07)], renal failure [OR: 6.4 (CI: 1.93–21.17)], and the incidence of newly
diagnosed DM [OR: 2.55 (CI: 1.26–5.19)]. No relation was found between the presence
of DM and the outcome of AP. 906 cases (mean age ± SD: 56.9 ± 16.7 years) had
data on all four components of MetS available. The presence of two, three, or four MetS
factors increased the incidence of an unfavorable outcome compared to patients with
no MetS factors.
Conclusion: OB, HT, and HL are independent risk factors for a number of
complications. HT is an independent risk factor for severity as well. Components of
MetS strongly synergize each other’s detrimental effect. It is important to search for and
follow up on the components of MetS in AP.
Keywords: acute pancreatitis, metabolic syndrome, obesity, diabetes mellitus, hypertension, hyperlipidemia,
severity, mortality
INTRODUCTION
Acute pancreatitis is a severe inflammatory condition with
increasing incidence and hospitalization worldwide (Forsmark
et al., 2016; Garg et al., 2019). AP has a variable severity
ranging from mild and self-limited to severe and fatal. The
mortality of the disease ranges approximately from 2 to 5%
and depends on the development of organ failure and local
complications, which are summarized in the revised Atlanta
classification (Banks et al., 2013). The major etiological factors are
gallstones and alcohol consumption (Forsmark et al., 2016), but
hypertriglyceridemia (HTG) and intake of certain medications
may also be in the background.
The severity and outcome of AP are influenced by the
metabolic comorbidities of the host (Working Group Iap/Apa
Acute Pancreatitis Guidelines, 2013; Goodger et al., 2016).
Metabolic syndrome is characterized by the clustering of
abdominal OB, HTG, low levels of high-density lipoprotein
(HDL), elevations in blood pressure and fasting glucose, or
diabetes (Alberti et al., 2009). MetS is associated with an increased
risk of development of and death from cardiovascular disease
and chronic kidney disease (Isomaa et al., 2001). The presence of
MetS was previously shown to be associated with a higher risk of
severe AP, higher mortality rate, and longer duration of stay in the
intensive care unit (Mikolasevic et al., 2016). However, in another
study, MetS did not affect the severity of AP (Sawalhi et al., 2014).
OB was previously shown to be independently associated with
the severity of AP (Sawalhi et al., 2014) and the development
of organ failure but not with mortality in AP (Smeets et al.,
2019). DM was associated with a higher risk of AP (Yang et al.,
2013) and negatively influenced the outcome of AP by raising
the incidence of renal failure, intensive care unit admission, and
length of hospital stay (LOS) (Miko et al., 2018). The presence of
HTG increased severity, complication rate, and mortality in AP
(Kiss et al., 2018).
Abbreviations: AP, acute pancreatitis; APR, Acute Pancreatitis Registry; BMI,
body mass index; CI, 95% confidence interval; DM, diabetes mellitus; HL,
hyperlipidemia; HPSG, Hungarian Pancreatic Study Group; HT, hypertension;
LOS, length of hospital stay; MetS, metabolic syndrome; OB, obesity; OR, odds
ratio; SD, standard deviation.
However, there is no data regarding a link between the
outcome of AP and the presence of arterial HT. Furthermore,
there is a lack of data on how the components of MetS, namely,
OB, DM, HT, and HL, influence the outcome of AP individually
or in combination. Therefore, in this study, we aimed to analyze
how the components of MetS influence the outcome of AP (1)
individually and (2) in combination.
MATERIALS AND METHODS
Patient Population and Study Design
The APR launched in 2011 by the Hungarian Pancreatic
Study Group is an international prospective registry for
patients suffering from AP. Besides pancreatic registries,
HPSG has already organized five registered clinical trials to
investigate AP with the acronyms PREPAST (Dubravcsik
et al., 2015), APPLE (Parniczky et al., 2016), PINEAPPLE
(Zsoldos et al., 2016), GOULASH (Marta et al., 2017),
and EASY (Hritz and Hegyi, 2015) and has submitted
three further pre-study protocols: GOULASH PLUS
(follow-up to the GOULASH study), EMILY (endoscopic
sphincterotomy for delaying cholecystectomy in mild acute
biliary pancreatitis), and LIFESPAN (lifestyle, prevention,
and risk of AP).
From June 2012 to September 2017, 1435 adult patients
with AP from 28 community and university hospitals were
prospectively enrolled (Supplementary Appendix S1).
Demographic and anthropometric data; history of HL, HT,
and DM; previous medical therapy and etiology; severity; local
and systemic complications; and mortality of AP were collected.
In this study, we aimed to maximize the number of
cases for each individual effect analysis. We had information
concerning OB from 1257 cases, HT from 1127 cases,
DM from 1257 cases, and HL from 1036 cases. Patients
were grouped based on the World Health Organization
(WHO) classification of BMI (≥30 or <30 kg/m2) and the
presence or absence of three other components, HT, HL,
and DM. However, in the “joint effect analysis,” we only
included cases where data from all four components of
Frontiers in Physiology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 1202
fphys-10-01202 September 19, 2019 Time: 10:17 # 3
Szentesi et al. Metabolic Syndrome and Acute Pancreatitis
MetS, OB, HL, HT, and DM were available (906 cases).
We conducted an additional analysis to confirm that the
cohorts noted above represent the total cohort of 1435
cases. Importantly, there were no significant differences in
demographics or the main outcome parameters between the
cohorts (Supplementary Appendix S2).
Data were collected by treating physicians with the help of
trained and experienced study administrators on the basis of a
standardized case report form and protocol in the prospective
APR. Accuracy of data recorded is secured by a four-level
quality check system involving both medical administrative
personnel and gastroenterologists. Data quality is presented
in Supplementary Appendix S3. The study protocol was
approved by the Scientific and Research Ethics Committee
of the Medical Research Council (22254-1/2012/EKU). All
patients provided written informed consent to participate
in the registry.
Definitions
Diagnosis of AP was made according to the recommendations
in the IAP/APA guidelines. At least two criteria of the following
three were present: upper abdominal pain, pancreatic enzyme
levels exceeding more than three times the upper normal level,
and features of pancreatitis on imaging (Working Group Iap/Apa
Acute Pancreatitis Guidelines, 2013). Severity and complications
of AP were determined according to the revised Atlanta
classification (Banks et al., 2013). OB was determined if BMI
was ≥30 kg/m2 (Jensen et al., 2014). HT was determined if
blood pressure was ≥140/90 mmHg or if the patient was on
anti-hypertensive medication. HL was defined by the presence
of either hypercholesterolemia or a low level of HDL or HTG.
The condition was regarded as HL when fasting cholesterol level
>200 mg/dL (5.2 mmol/L), HDL < 44 mg/dL (1.15 mmol/L;
female) or <35 mg/dL (0.9 mmol/L; male), triglyceride level
exceeded 150 mg/dL (1.7 mmol/L), or the patient was receiving
drug therapy for HL. The diagnosis of DM was made in
accordance with the American Diabetes Association Criteria
(American Diabetes Association, 2010) or if the patient was
receiving drug therapy for hyperglycemia.
The primary endpoints were mortality, severity, and
complications of AP and LOS.
Statistical Analyses
Case numbers and percentages were calculated for categorical
variables, mean with SD, and medians with 25 and 75% quartiles
(Q1 and Q3, respectively) and ranges were computed for
numerical variables in descriptive analysis.
The t-test was used for normally distributed data and the
Mann–Whitney U-test for non-normally distributed data to
compare two groups of independent samples. The relation
between categorical variables was inspected by the Chi-square test
and Z-test with the Bonferroni correction and ORs with 95% CIs.
Logistic regression was used to define the independent effect
of the MetS factors and age. A two-sided p-value of <0.05 was
regarded as statistically significant. The available-case analysis
was used for missing data. Statistical analyses were performed
with SPSS 25.0 software (IBM Corporation).
RESULTS
Individual Effect Analysis
A total of 1257 patients (mean age± SD: 55.7± 17.0 years, males
vs. females: 57.1 vs. 42.9%) were recruited for the “individual
effect analysis.” 371 patients (29.5%) had OB, 676 (60.0%) had
HT, 349 (33.7%) had HL, and 206 (16.4%) had DM (Table 1).
The major etiologies of AP were biliary stones in 37.8% of the
cases of the total cohort, alcohol in 18.5%, and HL in 3.7%. OB
increased the risk of biliary etiology [OR: 2.06 (CI: 1.61–2.64)].
Meanwhile, HTG-induced AP was more frequent in the presence
of HL (12.9 vs. 0.1%, p < 0.001) compared to the non-HL group
and in the presence of DM compared to the non-DM patient
group [OR: 2.34 (CI: 1.39–4.00)], respectively (Table 1).
Obesity (Figure 1)
Obesity was less common in males [OR: 0.75 (CI: 0.58–0.95)].
There was no difference between the ages of the OB and non-OB
groups (56.3 ± 15.2 vs. 55.4 ± 17.7, p = 0.398), although the age
distribution showed a larger proportion of obese patients in the
older age groups.
Obesity increased the risk of severe AP [OR: 2.15 (CI: 1.31–
3.54)] but showed no relation to the mortality rate [OR: 1.39
(CI: 0.66–2.96)]. OB did not influence the incidence of local
complications (Figure 2F) but increased the risk of systemic
complications [OR: 1.99 (CI: 1.30–3.05)], and respiratory [OR:
2.15 (CI: 1.26–3.65)] and renal [OR: 4.56 (CI: 2.23–9.32)] failure
in AP. Obese patients spent a longer time in the hospital (12.1 vs.
10.4 days, p = 0.008) (Figure 2G).
Independent effect
Logistic regression revealed that OB was an independent
predictive factor for renal failure [OR: 2.98 (CI: 1.33–
6.66)] (Table 2).
Hypertension (Figure 2)
Patients with HT were 17.6 years older on average (63.8± 14.1 vs.
46.2 ± 15.2, p < 0.001). Male gender was associated with a lower
risk of HT [OR: 0.66 (CI: 0.52–0.84)].
Hypertension increased the risks of severe AP [OR: 2.39 (CI:
1.30–4.38)], systemic complications [OR: 2.83 (CI: 1.64–4.88)],
and respiratory [OR: 3.14 (CI: 1.51–6.52)], heart [OR: 3.82 (CI:
1.11–13.11)], and renal failure [OR: 6.40 (CI: 1.93–21.17)]. HT
was also associated with longer hospitalization (11.8 vs. 10.5 days,
p = 0.020) (Figure 3E).
Independent effect
Logistic regression revealed that HT was a predictive factor for
severity [OR: 3.41 (CI: 1.39–8.37)], systemic complications [OR:
2.64 (CI: 1.27–5.51)], and renal failure [OR: 7.46 (CI: 1.61–34.49)]
as well (Table 2).
Hyperlipidemia (Figure 3)
Contrary to OB and HT, HL was associated with younger age
(54.0 ± 14.5 vs. 56.4 ± 17.8, p = 0.032) and a higher rate among
male patients [OR: 1.47 (CI: 1.12–1.92)].
For patients with HL, the chance of having mild AP was
lower [OR: 0.64 (CI: 0.49–0.85)], but HL had no significant effect
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TABLE 1 | Individual effect analysis.
Total cohort Obesity (n = 1257) Hypertension (n = 1127) Hyperlipidemia (n = 1036) Diabetes mellitus (n = 1257)
Non-OB OB Non-HT HT Non-HL HL Non-DM DM
n 1257 886 371 451 676 687 349 1051 206
% within groups 70.5 29.5 40.0 60.0 66.3 33.7 83.6 16.4
Age, sex, CCI
Average age 55.7 55.4 56.3 46.2 63.8∗ 56.4 54.0∗ 54.5 61.7∗
SD (average age) 17.0 17.7 15.2 15.2 14.1 17.8 14.5 17.3 13.9
Male (%) 57.1 59.3 52.0 61.9 51.8 55.6 64.8∗ 56.4 60.7
Female (%) 42.9 40.7 48.0∗ 38.1 48.2∗ 44.4 35.2 43.6 39.3
Average CCI 1.4 1.3 1.6 0.9 1.7 1.3 1.7 1.0 2.9
SD (CCI) 1.6 1.6 1.7 1.4 1.7 1.6 1.8 1.4 1.7
Etiology (%)
Biliary 37.8 33.6 47.7∗ 31.3 44.1 41.3 26.4 38.2 35.9
Alcoholic 18.5 21.1 12.1 20.2 12.4 21.4 17.2 19.0 15.5
HTG-induced 3.7 3.0 5.4 3.3 3.7 0.1 12.9∗ 2.8 8.7∗
Alcoholic + HTG-induced 1.8 1.9 1.6 1.6 1.9 0.0 6.6 1.8 1.9
Post-ERCP 2.6 3.0 1.6 3.1 2.8 2.9 0.9 2.6 2.9
Combined 8.0 7.1 10.0 11.1 7.0 7.7 7.2 7.9 8.3
Idiopathic 20.5 22.0 17.0 21.5 20.7 18.8 23.8 20.6 20.4
Other 7.1 8.1 4.6 8.0 7.4 7.7 5.2 7.2 6.3
Severity, mortality, LOS
Mild (%) 69.6 69.9 69.0 70.1 69.5 73.5 64.2∗ 69.7 68.9
Moderate (%) 25.1 26.1 22.6 26.8 23.4 22.1 29.5 24.9 25.7
Severe (%) 5.3 4.1 8.4∗ 3.1 7.1∗ 4.4 6.3 5.3 5.3
Mortality (%) 2.4 2.1 3.0 1.3 3.1 2.3 1.4 2.5 1.9
Average LOS 10.9 10.4 12.1∗ 10.5 11.8∗ 10.5 11.4 10.7 11.8
SD (LOS) 9.3 8.6 10.6 7.9 10.1 9.0 10.3 9.0 10.6
Complications (%)
Local complications 29.0 28.6 30.2 29.5 28.3 25.3 34.7∗ 29.1 28.6
Fluid collection 25.0 24.7 26.7 23.9 25.3 22.1 29.8∗ 24.9 27.2
Pseudocyst 7.6 7.8 7.3 6.9 9.3 6.0 10.6∗ 7.6 7.8
Necrosis 8.0 7.1 10.2 7.8 8.0 8.2 8.9 8.3 6.8
New onset diabetes 3.8 3.5 4.6 2.7 4.1 3.6 5.2 4.6 N/A
Systemic complications 7.6 6.0 11.3∗ 3.8 10.1∗ 6.6 9.5 7.0 10.2
Respiratory failure 4.6 3.5 7.3∗ 2.0 6.1∗ 4.5 4.9 4.1 7.3
Heart failure 1.8 1.4 3.0 0.7 2.5∗ 1.9 2.0 1.9 1.5
Renal failure 2.7 1.4 5.9∗ 0.7 4.1∗ 2.2 4.6∗ 2.8 2.4
Description of the study population. Demography, etiology, and outcome of AP. Significantly different values are marked in bold digits with an asterisk. Statistical analysis
is summarized in Supplementary Appendix S4.
on mortality. HL increased the risk of local complications [OR:
1.55 (CI: 1.17–2.05)], and, within local complications, acute fluid
collections and pseudocyst formation were more frequent [OR:
1.48 (CI: 1.11–1.99); OR: 1.81 (CI: 1.14–2.88), respectively]. HL
also increased the risk of renal failure [OR: 2.17 (CI: 1.06–4.43)].
Independent effect
Logistic regression revealed that HL was an independent
predictive factor for local complications [OR: 1.51 (CI: 1.10–
2.07)] and for a new diagnosis of DM [OR: 2.55 (CI: 1.26–
5.19)] (Table 2).
Diabetes Mellitus (Figure 4)
Patients with DM were older (61.7 ± 13.9 vs. 54.5 ± 17.3,
p < 0.001), while there was no difference in the gender
ratio between the DM and non-DM groups [OR: 1.19 (CI:
0.88–1.62)] (Supplementary Appendix S4). Statistical analyses
demonstrated no significant relation between DM and the
severity, mortality, and complications of AP.
Joint Effect Analysis
A total of 906 patients in our cohort (mean age ± SD:
56.9 ± 16.7 years, males vs. females: 57.3 vs. 42.7%) were
eligible for the “joint effect analysis.” 189 patients (20.9%) had
no components of MetS, 294 (32.5%) had OB, 560 (61.8%)
had HT, 316 (34.9%) had HL, and 162 (17.9%) had DM. We
formed groups of patients according to the factor combinations
they had and compared the outcome parameters between the
different factor combinations and the group of no MetS factors
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FIGURE 1 | Individual effect analysis. OB and the outcome of AP. (A) The share of male patients was lower in the OB group [∗OR: 0.75 (CI: 0.58–0.95)]. (B) There is
no difference in the average age between the OB and non-OB groups (p = 0.398). (C) Obese patients have more than double the risk of severe AP [∗OR: 2.15 (CI:
1.31–3.54)]. (D) Obese patients did not have a higher risk of mortality. (E) Obese patients spent more time in the hospital (∗p = 0.008). (F) More local complications
were observed in the OB group, although the difference was not significant. (G) Obese patients had a higher risk of systemic complications [∗OR: 1.99 (CI:
1.30–3.05)], respiratory failure [∗OR: 2.15 (CI: 1.26–3.65)], and renal failure [∗OR: 4.56 (CI: 2.23–9.32)].
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FIGURE 2 | Individual effect analysis. HT and the outcome of AP. (A) There are fewer male patients with HT [∗OR: 0.66 (CI: 0.52–0.84)]. (B) Patients with HT are
older than patients without it (∗p < 0.001). (C) Hypertensive patients have more than double the risk of the severe form of AP [∗OR: 2.39 (CI: 1.30–4.38)]. (D) The
risk of mortality was not higher in the HT group. (E) Patients with HT spent more time in the hospital (∗p = 0.020). (F) There was a higher incidence of fluid collection,
pseudocysts, and new onset diabetes, although the difference was not significant. (G) Hypertensive patients have a higher risk of systemic complications [∗OR: 2.83
(CI: 1.64–4.88)], respiratory failure [∗OR: 3.14 (CI: 1.51–6.52)], heart failure [∗OR: 3.82 CI: (1.11–13.11)], and renal failure [∗OR: 6.40 (CI: 1.93–21.17)].
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TABLE 2A | Independent effect of components of MetS, including age, in the
logistic regression.
MetS component Outcome parameter OR 95% CI
Severity 1.38 0.73–2.58
Mortality 1.06 0.38–2.96
Local complications 0.99 0.72–1.37
Fluid collection 1.05 0.75–1.48
Pseudocyst 0.85 0.50–1.44
OB Necrosis 1.48 0.89–2.45
New onset of diabetes 1.52 0.73–3.14
Systemic complication 1.35 0.79–2.30
Respiratory failure 1.52 0.77–3.02
Heart failure 2.45 0.88–6.78
Renal failure 2.98 1.33–6.66
Severity 3.41 1.39–8.37
Mortality 4.50 0.91–22.20
Local complications 1.22 0.85–1.75
Fluid collection 1.42 0.97–2.08
Pseudocyst 1.55 0.85–2.81
HT Necrosis 1.36 0.76–2.43
New onset of diabetes 1.56 0.66–3.65
Systemic complication 2.64 1.27–5.51
Respiratory failure 1.59 0.63–4.00
Heart failure 1.41 0.36–5.54
Renal failure 7.46 1.61–34.49
Severity 1.40 0.73–2.67
Mortality 0.61 0.19–2.00
Local complications 1.51 1.10–2.07
Fluid collection 1.32 0.94–1.84
Pseudocyst 1.58 0.95–2.61
HL Necrosis 1.06 0.63–1.78
New onset of diabetes 2.55 1.26–5.19
Systemic complication 1.34 0.77–2.32
Respiratory failure 0.90 0.43–1.90
Heart failure 1.59 0.54–4.67
Renal failure 1.93 0.85–4.38
Severity 0.48 0.20–1.16
Mortality 0.46 0.10–2.14
Local complications 0.84 0.56–1.28
Fluid collection 1.02 0.67–1.56
Pseudocyst 1.01 0.53–1.91
DM Necrosis 0.53 0.24–1.14
New onset of diabetes N/A N/A
Systemic complication 0.92 0.48–1.74
Respiratory failure 1.48 0.68–3.20
Heart failure 0.32 0.07–1.53
Renal failure 0.43 0.15–1.22
OB is an independent predictive factor for renal failure; HT for severity; and systemic
complications, renal failure, and hyperlipidemia for local complications and for
a new diagnosis of diabetes mellitus. OR, odds ratio; CI, confidence interval.
Statistically significant values (ORs with CIs) are marked in bold digits.
one by one (Supplementary Appendix S5). The presence of
two, three, or four MetS factors significantly increased the
rate of worse outcome parameters by 9.5, 24.1, and 66.7%,
respectively (Figure 5).
TABLE 2B | Logistic regression.
Severity 1.01 0.99–1.03
Mortality 1.02 0.98–1.05
Local complications 0.99 0.98–1.00
Fluid collection 0.99 0.98–1.00
Pseudocyst 1.00 0.98–1.01
Age Necrosis 0.99 0.97–1.00
New onset of diabetes 1.01 0.99–1.04
Systemic complication 1.01 0.99–1.03
Respiratory failure 1.03 1.01–1.06
Heart failure 1.05 1.01–1.09
Renal failure 1.00 0.97–1.03
Older age was demonstrated to be independently associated with respiratory and
heart failure in our study. Statistically significant values (ORs with CIs) are marked
in bold digits.
DISCUSSION
Summary of Findings
Our results demonstrated in a large database of prospectively
collected cases that the components of MetS deteriorate
the outcome of AP. OB was shown to be an independent
risk factor for renal failure and was associated with a
longer hospital stay. HT was proved to be an independent
risk factor for severity of AP and increased the risk of
renal failure, while patients with HT spent a longer time
in hospital. HL increased the risk of local complications,
renal failure, and the new diagnosis of DM. Preexisting
DM did not change the outcome of AP. Our study
demonstrated that the more components of MetS the
patients had, the higher the rate of worse outcome
parameters was observed.
The incidence of AP is increasing, and this is partly due to
the rising prevalence of OB, which stimulates gallstone formation
and increases HL, both causing AP (Yadav and Lowenfels, 2013;
Bonfrate et al., 2014). Indeed, biliary AP was more frequent in
obese patients compared to the total cohort in our study.
To date, several cohort studies and a systematic review
have reported that OB increases the severity, mortality, and
occurrence of local and systemic complications in AP. However,
these results are conflicting on the link between OB and
outcomes in AP (Dobszai et al., 2019). The reason behind this
conflict may be that most of the included studies reported
unadjusted analysis; therefore, it cannot be clarified whether
OB is an independent prognostic factor in AP or not (Dobszai
et al., 2019). In a recent individual patient data meta-analysis,
where confounders were adjusted, OB was independently
associated with the development of organ failure and multiple
organ failure in AP; however, there was no relation between
OB and mortality, necrosis, and intervention (Premkumar
et al., 2015). These data are in agreement with our results,
where OB was demonstrated to be an independent predictive
factor for renal failure but did not modify the mortality
rate (Table 2).
A possible mechanism by which OB is associated with a higher
risk of renal failure is lipotoxicity.
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FIGURE 3 | Individual effect analysis. HL and the outcome of AP. (A) There are more male patients with HL [∗OR: 1.47 (CI: 1.12–1.92)]. (B) Patients with HL are
younger than patients without it (∗p < 0.001). (C) Hyperlipidemic patients have a lower chance of having mild AP [∗OR: 0.65 (CI: 0.49–0.85)]. (D) Patients with HL
did not have a higher risk of mortality. (E) Patients with HL spent more time in the hospital (∗p = 0.053). (F) HL increases the risk of local complications [∗OR: 1.55
(CI: 1.17–2.05)], acute fluid collection [∗OR 1.48 (CI: 1.11–1.99)], and pseudocysts [∗OR 1.81 (CI: 1.14–2.88)]. (G) Hyperlipidemic patients have a higher risk of renal
failure [∗OR 2.17 (CI: 1.51–4.43)].
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FIGURE 4 | Individual effect analysis. DM and the outcome of AP. (A) There is no significant difference in sex between the two groups. (B) Patients with diabetes are
older than patients without it (∗p < 0.001). (C,D) Diabetic patients did not have a higher risk of moderately severe or severe AP or mortality in our cohort. (E) There is
no difference in LOS between the two groups (p = 0.139). (F,G) As regards local or systemic complications, there are no differences between diabetic and
non-diabetic patients in our cohort.
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FIGURE 5 | Joint effect analysis. The effect of MetS factor combinations on the outcome of AP. The more MetS factors are present, the more significantly higher
incidence of the different outcome parameters can be observed. Statistical analysis is summarized in Supplementary Appendix S5.
Obesity is associated with elevated levels of intrapancreatic fat
and with elevated visceral fat surrounding the pancreas (Smeets
et al., 2019). This hypothesis is also supported by experimental
data. A long-term high-fat diet caused acinar cell injury and
pancreatic fibrosis via fat accumulation in pancreatic acinar
cells (Matsuda et al., 2014). It has also been suggested that
intrapancreatic fat, which may cause metabolic and inflammatory
processes, is associated with OB (Majumder et al., 2017). In
addition, in the presence of intrapancreatic fat, pancreatic lipases
are released in AP digest adipocytes, resulting in an outflow
of unsaturated fatty acids into the circulation; they are toxic
and can act as proinflammatory mediators and are implicated
in the development of systemic inflammation and organ failure
(Navina et al., 2011).
Hypertension was independently associated with the severity
of AP and the rate of renal failure in our study. To the best
of our knowledge, no study has ever analyzed the effect of
arterial HT on the outcome of AP. The underlying mechanisms
by which HT deteriorates the outcome of AP is unclear. It
has been suggested that the sympathetic nervous system may
act as an amplifier of the blood pressure elevation and may
be involved in the development of HT-related complications.
Sympathetic activation favors the development and progression
of vascular hypertrophy and remodeling and contributes
to impairing arterial distensibility and vascular compliance
(Seravalle et al., 2014). The presence of a hyperadrenergic state
and microvascular and macrovascular structural changes in the
arteries may be responsible for the deteriorative effects of HT
(Smits and van Geenen, 2011).
Preexisting HL was shown to be independently associated
with local complications and renal failure in our study. Our
results are in line with those of a recent meta-analysis, which
reported that the presence of HTG significantly elevated the
risk of renal failure but did not increase the risk of mortality
in AP (Kiss et al., 2018). However, HTG also significantly
elevated the risk of severe AP in this meta-analysis (Kiss et al.,
2018), while HL did not increase the risk of severe AP in our
study. This discrepancy can be explained by the fact that (1)
most of the studies included in the meta-analysis reported an
unadjusted analysis, and, therefore, the independent effect of
HTG in AP cannot be elucidated; and (2) the HL group in
our study included patients with either hypercholesterinemia
and/or HTG, while patients with HTG only were included in the
meta-analysis. One possible mechanism by which HL increases
local and systemic complications in AP is the formation and
toxic effect of unsaturated fatty acid by pancreatic lipases. In
addition, in the case of HTG, the chylomicron concentration is
elevated. As a result, blood viscosity increases, thus impairing
blood flow and causing pancreatic ischemia and acidosis
(Pedersen et al., 2016).
There is a special relationship between the exocrine and
endocrine pancreas. Experimental data suggest that insulin has
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a local protective effect on acinar cells during pancreatitis.
Pancreatitis evoked by L-arginine causes severe acinar cell
necrosis in most of the territory of the exocrine pancreas.
However, acinar cells located around the islets of Langerhans
remain totally intact (Hegyi et al., 1997). In addition, we also
confirmed that if the beta cells are destroyed by streptozotocin
treatment prior to the induction of AP, this locally visible
protective effect disappears irrespectively of exogenous insulin
administration (Takacs et al., 2001). Unfortunately, in our
registry analysis, we could not investigate the local effects
of insulin. Here we showed that preexisting DM does not
significantly influence severity, mortality, or rate of complications
in AP in our cohort. We hypothesized that our cohort was
not sufficiently large to determine a significant difference.
We have recently published a meta-analysis in which DM
significantly elevated both local and systemic complications
when an analysis was conducted of 354,880 cases (Miko
et al., 2018). However, it is clearly impossible to collect this
number of patients in a single cohort. Furthermore, intensive
care unit mortality only grew significantly with higher mean
blood glucose concentration in non-DM patients but not in
DM patients (Egi et al., 2008; Pedersen et al., 2016). In
agreement with our results, critically ill patients with DM
did not have higher mortality compared to non-DM patients
(Whitcomb et al., 2005).
Older age was demonstrated to be independently associated
with pulmonary and heart failure in our study (Table 2B). Older
age has been investigated extensively as a marker of severity
and mortality in AP and is included in the APACHE II score,
Ranson score, Bedside Index of Severity in AP (BISAP) score,
and Japanese Severity Score (JSS) as a marker of severity (Graham
et al., 2010). However, after adjusting for comorbid disease, only
the very extreme age (>85 years old) was associated with 30-
day in-patient mortality and persistent organ failure in a recent
prospective, multicenter study (Mounzer et al., 2012). Our results
are in line with a recent cohort analysis that found that elderly
patients had a significantly higher risk of developing systemic
complications, while high mortality in this group is due to the
effect of severe comorbidities (Szakacs et al., 2018).
Patients with AP often develop diabetes during and after the
attack of AP (Moran et al., 2018); however, the risk of DM
was not fully evaluated. The severity of AP, its etiology, and
individuals’ age and sex had a minimal effect on the development
of newly diagnosed diabetes in AP (Moran et al., 2018). We
showed that HL is an independent risk factor for the development
of newly diagnosed DM in AP. High cholesterol and triglyceride
levels increase the risk of DM, a finding supported by earlier
studies (von Eckardstein and Sibler, 2011; Das et al., 2014).
We can hypothesize that the predisposition to DM caused by
dyslipidemia was manifested during AP. This finding emphasizes
the need for a thorough screening for DM in AP patients with HL.
Moreover, all AP patients should be followed and screened for
DM as hyperglycemia stimulates the proliferation of pancreatic
stellate cells and collagen secretion, while hypoinsulinemia
inhibits acinar cell growth and synthesis of pancreatic enzymes
and therefore facilitates fibrosis of the pancreas and might cause
chronic pancreatitis (Czako et al., 2009).
Strengths and Limitations
The main strength of the present study is that it has a large
sample size of prospectively collected cases from hospitals in
multiple countries, including tertiary and non-tertiary centers.
Furthermore, a logistic regression analysis was applied to control
confounding variables, and the independent prognostic factors
of the components of MetS were analyzed for AP. Finally, our
study is the first to report the relation between the outcome
of AP and the presence of arterial HT and to analyze the
influence of the combined presence of the components of MetS
on the outcome of AP.
The present study has limitations. First, since APR is a
multicenter prospective registry and not an observational trial,
our findings are affected by confounding factors or selection
bias. Second, our study design is cross-sectional, thus precluding
any causal interferences about the directionality of the relations
observed in our study; therefore, long-term clinical outcomes
could not be evaluated. Accordingly, long-term prospective
trials are needed in the future. Third, our study assessed the
effect of HL, not HTG, thus not fully suiting the definition
of MetS. Fourth, peripancreatic fluid accumulations could not
always be adequately defined according to the modified Atlanta
classification. Acute fluid collection and acute necrotic fluid
collection, pseudocysts, and walled-off pancreatic necrosis could
not always be differentiated because abdominal CT was not
performed in all cases. Therefore, peripancreatic fluid collections
without a definitive wall were named as acute fluid collections and
with a wall as pseudocysts.
CONCLUSION
In conclusion, the components of MetS deteriorate the outcome
of AP. OB, HT, and HL are independent risk factors for a number
of complications. HT is an independent risk factor for severity as
well. The more elements of MetS are present, the higher the risk
for complications. It is important to search for and follow up on
the components of MetS in AP.
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